Introduction {#sec1}
============

Increased proliferation of vascular smooth muscle cells (VSMCs) is an important phenomenon in the pathogenesis of atherosclerosis, which is the underlying pathology for many cardiovascular diseases such as myocardial infarction or stroke \[[@cit0001], [@cit0002]\]. Cell cycle regulation is considered to be an essential mechanism for the inhibition of cell proliferation \[[@cit0003]\]. The cell cycle is regulated by the synchronized action of cyclin-dependent kinases (CDKs), in association with their specific regulatory cyclin proteins. Therefore, functional activation of CDK-cyclin is required for cell cycle progression \[[@cit0004], [@cit0005]\]. The kinase activity of these CDK-cyclin complexes is inhibited by two classes of cyclin-dependent kinase inhibitors (CKIs), including the INK4 family (p16INK4a and p15INK4b) and cip family (p21cip1 and p27kip1) \[[@cit0006]--[@cit0008]\]. p53 is known to be an up-regulator of p21 in cell cycle arrest. Several findings have demonstrated that the product of p53 is responsible for the G1 checkpoint. In response to genotoxic stress and drugs, the level of p53 protein was increased, and a transient arrest of cell cycle progression in the G1 phase occurred \[[@cit0009]\] or apoptosis was triggered \[[@cit0010], [@cit0011]\]. Thus, induction of p53 has been considered to be an effective strategy for molecular target therapy of atherosclerosis.

Vascular smooth muscle cell proliferation induced by platelet-derived growth factor (PDGF) has been considered to be crucial for the development of vascular diseases. The PDGF interacts with its receptor in VSMCs. PDGF-BB can activate PLC γ, Akt, and ERK1/2 signaling pathways to induce cell proliferation, cell migration, and angiogenesis of VSMCs \[[@cit0012]\]. A study has reported that stimulating p53 activity and inducing the expression of p21waf1/cip1 antagonizes the down-regulation of the levels and/or activities of these molecules by PDGF-BB \[[@cit0013]\]. Therefore, the identification of novel compounds that inhibit PDGF-dependent cell proliferation has the potential to improve existing therapeutic strategies and limit late cardiovascular complications \[[@cit0014]\].

Hinokitiol ([Figure 1 A](#f0001){ref-type="fig"}), also known as β-thujaplicin, is a natural tropolone-related compound found in the heartwood of Cupressaceae plants that has a wide range of biochemical and pharmacological activities \[[@cit0015]\]. This compound has received more attention from several investigators recently, as it has been used in hair tonics, toothpastes, cosmetics, and food as an antimicrobial agent \[[@cit0016]\], and several studies have confirmed that it has marked anti-bacterial \[[@cit0017]\], anti-tumor \[[@cit0018]\] and neuroprotective activities \[[@cit0019]\], as well as antioxidant capacities \[[@cit0020]\]. Recent studies have reported that hinokitiol induces DNA damage and autophagy followed by cell cycle arrest in cancer cells \[[@cit0021], [@cit0022]\]. Our previous studies have demonstrated that hinokitiol has potent *in vitro* and *in vivo* antithrombotic \[[@cit0023]\], *in vivo* neuroprotective \[[@cit0024]\] and *in vitro* and *in vivo* antitumor effects \[[@cit0025]\]. However, little is known about the effects of hinokitiol on cardiovascular diseases, and the findings of the associated signaling mechanisms remain unclear. Therefore, we investigated whether hinokitiol attenuates VSMC proliferation induced by PDGF-BB or serum *in vitro*.

![Effects of hinokitiol on platelet-derived growth factor (PDGF)-BB and serum-induced proliferation of vascular smooth muscle cells (VSMCs). **A** -- Chemical structure of hinokitiol. **B, C** -- Serum-starved VSMCs were pretreated in the presence or absence of hinokitiol (1--50 μM), and then stimulated with (**B**) 10 ng/ml PDGF-BB or (**C**) 10% fetal bovine serum (FBS) for 48 h. Cell proliferation was evaluated by MTT assay. **D** -- VSMCs were co-treated with hinokitiol (1--200 μM) for 24 or 48 h, and cytotoxicity was determined using the LDH assay. Data are presented as mean ± SEM (*n* = 3). \**p* \< 0.05 compared to control group, ^\#^*p* \< 0.05 compared to PDGF-BB or FBS stimulated cells](AMS-14-32528-g001){#f0001}

Material and methods {#sec2}
====================

Materials {#sec2.1}
---------

Hinokitiol (product number: 469521; purity: ≥ 98.5%) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma Chemical Company (St. Louis, MO, USA). Recombinant PDGF-BB was purchased from Pepro-Tech (Rocky Hill, NJ, USA). Anti-mouse and anti-rabbit immunoglobulin G-conjugated horseradish peroxidase (HRP) was purchased from GE Healthcare (Sunnyvale, CA, USA) and/or Jackson-Immuno Research (West Grove, PA, USA). Anti-phospho-ERK1/2 (Thr^202^/Tyr^204^), anti-phospho-AKT (Ser^473^), antiphospho-PI3K, and antiphospho-JAK2 monoclonal antibodies (mAbs) were purchased from Cell Signaling (Beverly, MA, USA). Anti-p53 was obtained from GeneTex Inc (Irvine, CA). The WWP-luc (p21cip/Waf1 promoter) construct (Addgene plasmid 16451) and the PG13-luc plasmid with p53 binding sites (Addgene plasmid 16642) were kindly provided by Dr. Ming Jen Hsu. The Dual-Glo luciferase assay system was purchased from Promega (Madison, WI). The Hybond-P polyvinylidene difluoride (PVDF) membrane and enhanced chemiluminescence (ECL) Western blotting detection reagent and analysis system were obtained from GE Healthcare (Sunnyvale, CA, USA). All other chemicals used in this study were of reagent grade.

Animal care and cultivation of rat primary VSMCs {#sec2.2}
------------------------------------------------

All animal experiments and care were performed according to the National Research Council Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee (IACUC) of Taipei Medical University. As previously described \[[@cit0026]\], VSMCs were enzymatically isolated from the thoracic aortas of male Wistar rats (250--300 g). VSMCs were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20 mM/l HEPES, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 2 mM/l glutamine at 37°C in a humidified atmosphere of 5% CO~2~. VSMCs at passage 4--8 were used in all experiments.

MTT assay {#sec2.3}
---------

VSMCs (2 × 10^4^ cells/well) were seeded on 24-well plates and cultured in DMEM containing 10% FBS for 24 h. The cell was then treated according to the experimental designs. The cell number was measured using a colorimetric assay based on the ability of mitochondria in viable cells to reduce the MTT as previously described \[[@cit0027]\]. The cell number index was calculated as the absorbance of treated cells/control cells.

Lactose dehydrogenase (LDH) assay {#sec2.4}
---------------------------------

Cytotoxicity was assessed by LDH assay in the supernatant medium using a non-radioactive cytotoxicity kit according to the protocol of the manufacturer (BioVision Inc, Milpitas, CA, USA). VSMCs were seeded on a round-bottom 96-well culture plate in triplicate sets of wells. After incubation, cells were treated with various concentrations of hinokitiol (1--200 μM) for 24 and 48 h. VSMCs were lysed followed by two freeze/thaw cycles. The plate was centrifuged at 250 g for 4 min, and 50 μl of supernatant was transferred from each well to a fresh 96-well flat-bottom plate. Then 50 μl of the reconstituted substrate mix was added to each well of the plate. The plate was covered with foil to protect it from light, and then the plate was incubated at room temperature for 30 min. The reaction was stopped by the addition of 50 μl of stop solution, and LDH was determined by measuring the absorbance at 490 nm. The fold activity of LDH was calculated from the following equation: \[(experimental LDH release)/(vehicle LDH release)\].

DNA synthesis assay {#sec2.5}
-------------------

VSMCs (2 × 10^5^ cells/dish) were seeded in a 96-well microplate for 24 h and then serum-starved for 24 h. Following preincubation with hinokitiol for 20 min, the cells were treated with PDGF-BB (10 ng/ml) and 10% FBS serum for 48 h. DNA synthesis was assessed using BrdU incorporation assay kits (Roche Diagnostics, Rotkreuz, Switzerland) according to the manufacturer's instructions. DNA synthesis in VSMCs was assessed by the incorporation of BrdU. In addition, confocal microscopy was also used to observe the expression of BrdU positive cells. VSMCs (1 × 10^5^ cells/cover slip) were placed on cover slips and allowed to adhere in a cell culture incubator overnight. VSMCs were treated as experimental design, and fixed with BrdU fixed solution (Roche Diagnostics, Rotkreuz, Switzerland). After incubation with 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 60 min, the preparation was incubated overnight with a primary anti-BrdU Ab (1 : 80). Cells were then washed three times with PBS and exposed to goat anti-mouse IgG secondary antibody, Alexa Fluor 488 conjugate (1 : 1000) (Thermo Fisher Scientific, Waltham, MA, USA) for 2 h. The samples were counter-stained with DAPI and mounted with mounting buffer (Vector Laboratories, Burlingame, CA, USA) under a glass cover slip on a Leica TCS SP5 Confocal Spectral Microscope Imaging System using an argon/krypton laser (Mannheim, Germany).

Immunoblotting {#sec2.6}
--------------

Immunoblotting was performed as previously described \[[@cit0028]\]. Serum-starved VSMCs (2 × 10^5^ cells/dish) were treated with hinokitiol (1--100 μM) or DMSO for 20 min, followed by the addition of PDGF-BB (10 ng/ml) for the indicated times. After treatment, proteins were extracted with lysis buffer. The lysates were centrifuged, the supernatant protein (50 μg) was collected and subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were electrophoretically transferred onto 0.45-μm polyvinylidene difluoride (PVDF) membranes. The blots were blocked with TBST (10 mM Tris-base, 100 mM NaCl, and 0.01% Tween 20) containing 5% bovine serum albumin (BSA) for 1 h and were then probed with various primary antibodies. The membranes were incubated with HRP-linked anti-mouse IgG or anti-rabbit IgG (diluted 1 : 3000 in TBST) for 1 h. Immunoreactive bands were detected by an enhanced chemiluminescence (ECL) system. The bar graph depicts the ratios of quantitative results obtained by scanning reactive bands and quantifying the optical density using video densitometry (Bio-profil; Biolight Windows Application V2000.01; Vilber Lourmat, France).

Dual luciferase reporter assay {#sec2.7}
------------------------------

Cells were transfected with PG13-luc or p21cip/Waf1-luc using Turbofect reagent (Upstate Biotechnology, Lake Placid, NY). Cells with and without treatments were then harvested, and the luciferase activity was determined using a Dual-Glo luciferase assay system kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Normalization was performed with *Renilla* luciferase activity as the basis.

Statistical analysis {#sec2.8}
--------------------

The experimental results are expressed as mean ± SEM. One-way analysis of variance (ANOVA) was used for multiple comparisons (Sigma Stat v3.5 software). If there was significant variation between treated groups, the Student-Newman-Keuls test was applied. A *p-*value \< 0.05 was considered to be statistically significant.

Results {#sec3}
=======

Hinokitiol inhibits PDGF-BB and serum induced proliferation of VSMCs {#sec3.1}
--------------------------------------------------------------------

PDGF-BB (10 ng/ml) or serum (10% FBS) induced VSMC proliferation in a concentration-dependent manner ([Figures 1 B](#f0001){ref-type="fig"}, [C](#f0001){ref-type="fig"}). In addition, it was found that VSMC pretreated with hinokitiol inhibits cell proliferation after both PDGF-BB and serum stimulation in a concentration-dependent manner. These results suggest that the inhibitory effects of hinokitiol on VSMC proliferation are not specific to PDGF-BB. As anti-proliferative activity is regularly conveyed by cytotoxicity, this study also measured the cytotoxic effects of hinokitiol on VSMCs, and found no evidence of cytotoxicity up to 50 μM in both 24 and 48 h ([Figure 1 D](#f0001){ref-type="fig"}) incubation. Thus, these results indicated that hinokitiol appeared to inhibit VSMC proliferation without cytotoxicity.

Hinokitiol inhibits PDGF-BB and serum induced DNA synthesis in VSMCs {#sec3.2}
--------------------------------------------------------------------

The BrdU incorporation assay was used to further investigate the effects of hinokitiol on PDGF-BB and serum stimulated DNA synthesis. The results revealed that hinokitiol significantly inhibited the BrdU incorporation induced by PDGF-BB and serum stimulation in a dose-dependent manner ([Figures 2 A](#f0002){ref-type="fig"}, [B](#f0002){ref-type="fig"}). Moreover, [Figure 2 C](#f0002){ref-type="fig"} also shows that the treatment of hinokitiol (10 μM) significantly reduces the BrdU positive VSMCs induced by PDGF-BB through the immunofluorescence staining assay. These results indicate that the inhibitory effect of hinokitiol targets DNA synthesis rather than cytotoxicity to cause the loss of cellular DNA.

![Hinokitiol inhibits PDGF-BB and serum induced DNA synthesis in VSMCs. Serum-starved VSMCs were pretreated in the presence or absence of hinokitiol (1--10 μM), and then stimulated with (**A**) 10 ng/ml PDGF-BB or (**B**) 10% fetal bovine serum (FBS) for 48 h. DNA synthesis was assessed using BrdU incorporation assay kits. Data are presented as mean ± SEM (*n* = 3). \**p* \< 0.05 compared to control group, ^\#^*p* \< 0.05 compared to PDGF-BB or FBS stimulated cells. **C** -- VSMCs (1 × 10^5^ cells/cover slip) were placed on cover slips, allowed to adhere overnight and then serum starved for 24 h. The VSMCs were pre-treated in the presence or absence of hinokitiol (10 μM), and then stimulated with 10 ng/ml PDGF-BB for 48 h. BrdU positive VSMCs were directly observed by confocal microscopy. Representative immunofluorescence staining for BrdU was revealed in green and nuclear staining DAPI was revealed in blue. The white bar indicates 100 μm](AMS-14-32528-g002){#f0002}

Role of hinokitiol in signaling pathways induced by PDGF-BB {#sec3.3}
-----------------------------------------------------------

We next examined the signaling pathway(s) involved in the inhibitory effect of hinokitiol on VSMC proliferation in response to PDGF-BB stimulation. The phosphorylation levels of ERK1/2, Akt, PI3K and JAK2 were increased by PDGF-BB treatment, whereas these modifications were not significantly reversed by hinokitiol treatment. The total protein levels of ERK and Akt and α-tubulin did not change during the course of stimulation with PDGF-BB in the presence or absence of hinokitiol ([Figures 3 A--D](#f0003){ref-type="fig"}). These data suggest that ERK1/2, Akt, PI3K and JAK2 signaling pathways are not involved in the anti-proliferative effects of hinokitiol in VSMCs in response to PDGF-BB.

![Effect of hinokitiol on PDGF-BB signaling pathway in VSMCs. **A** -- Confluent cells were pre-treated in the presence or absence of hinokitiol (1--100 μM) in a serum-free medium, and then stimulated with 10 ng/ml PDGF-BB for 10 min. The cells were lysed, and the levels of (**A**) p-ERK1/2, (**B**) p-Akt, (**C**) p-PI3K and (**D**) p-JAK2 were analyzed by SDS-PAGE and immunoblotting. The respective total proteins and a-tubulin were used for the normalization of phosphorylated ones. Data are expressed as mean ± SEM (*n* = 3). \**p* \< 0.05 compared to the PDGF-BB stimulated cells](AMS-14-32528-g003){#f0003}

Hinokitiol induces p21 expression in VSMCs {#sec3.4}
------------------------------------------

p21 was found to be up-regulated concentration dependently in VSMCs in response to hinokitiol treatment ([Figure 4 A](#f0004){ref-type="fig"}). A representative luciferase assay for p21 is shown in [Figure 4 B](#f0004){ref-type="fig"}. Hinokitiol at a dose of 5 μM significantly (*p* \< 0.05) increased p21 protein expression in VSMCs.

![Effect of hinokitiol on p21 expression and p53 activation in VSMCs. **A, C** -- VSMCs were pre-treated in the presence or absence of hinokitiol for 24 h (**A**) or the indicated time period (**C**). The cells were then lysed, and the level of p21 (**A**) and p-p53 (**C**) was analyzed by immunoblotting. **B, D** -- VSMCs were transiently transfected with p21cip/Waf1-luc (**B**) or PG-13-luc (**D**) and *Renilla*-luc for 48 h. Transfected VSMCs were pre-treated in the presence or absence of hinokitiol for 24 h. The luciferase activity was then determined. Data are expressed as mean ± S.E.M; (*n* = 3), \**p* \< 0.05 compared to the control group](AMS-14-32528-g004){#f0004}

Hinokitiol induces p53 phosphorylation and its binding effects in VSMCs {#sec3.5}
-----------------------------------------------------------------------

As p53 is essential for proliferation processes in VSMCs, the effect of hinokitiol on p53 phosphorylation was assessed. [Figure 4 C](#f0004){ref-type="fig"} shows that treatment of VSMC with hinokitiol (5 μM) for 10 and 20 min caused enhanced phosphorylation of p53, whereas it is down-regulated at 30 and 60 min treatment periods. The p53 luciferase reporter gene assay demonstrated that p53 promoter activity was induced after treatment with hinokitiol ([Figure 4 D](#f0004){ref-type="fig"}).

Discussion {#sec4}
==========

Abnormal proliferation of VSMCs in arterial walls acts as a critical contributing factor in the pathogenesis of atherosclerosis and restenosis after angioplasty, and also in the development of hypertension \[[@cit0029]\]. We demonstrated that hinokitiol potently inhibited PDGF-BB and serum-stimulated proliferation by increasing inhibition of newly synthesized DNA without affecting apoptosis in VSMCs. Hinokitiol up-regulated the expression level of p21, the upstream regulatory protein in VSMCs.

p21^Cip1^, an important member of the CIP/KIP family of CDKIs, has been described to specifically normalize the cell cycle transition \[[@cit0030]\], and it inhibits G1 cyclin/Cdks activity by blocking cell cycle progression, such as cyclin E- and cyclin A-CDK2 complexes \[[@cit0031], [@cit0032]\]. In addition, p21^Cip1^ participates in modulation of cell differentiation and apoptosis \[[@cit0006]\]. In the western blot analysis, we observed that the expression of p21 was significantly and dose dependently increased by hinokitiol treatment. Elevated p21 led to a marked increase in p21 promoter gene expression. Consequently, it can be proposed that p21 is another potential effector to control the G1/S transition. Transcriptional regulation of p21 is known to occur via both p53 dependent and independent mechanisms \[[@cit0033]\]. In the conventional p53 dependent pathway, DNA damage results in p53 activation. p53 then interacts with response elements present on the promoter region of p21 to increase expression of p21. Normally, p21 acts as a major effector of p53 to control the G1 cell cycle checkpoint \[[@cit0008]\]. In the present study, the results also showed that the upregulation of the p53 protein phosphorylation by hinokitiol led to increased p53 luciferase reporter gene overexpression. These results may suggest that hinokitiol potentially blocks VSMC proliferation via activation of p53 and p21.

The current study further investigated the effects of hinokitiol on the PDGF-signaling pathway in PDGF-BB-stimulated VSMCs. PDGF is a potent growth factor produced by VSMCs, endothelial cells, and platelets in injured vascular wall \[[@cit0012], [@cit0034]\]. After PDGF-BB is bound to its receptor in smooth muscle cells, three major signal transduction pathways -- p-PLCγ1, p-AKt, and p-p-ERK1/2 -- can be activated \[[@cit0035]\]. In this study, we found that hinokitiol had no effect on the expression of p-ERK1/2, p-Akt, and p-JAK2. Therefore, these results suggest that hinokitiol may inhibit the PDGF-BB or serum-stimulated proliferation of VSMCs, through enhancing the p21 and p53 signaling pathway.

PI3K/Akt is known as one of the principal signaling molecules for cell proliferation and survival mediated by extracellular stimuli \[[@cit0036]\]. Substances for inhibition of the PI3K/Akt pathway such as AS605240, TG100--115, PIK-75 and TGX-221 have been widely studied in treatment of hypertension and angina, and show an array of biological effects in the cardiovascular system \[[@cit0037]\]. The PI3K/Akt inhibitors have also been used widely as pharmaceutical tools and associated signaling pathways in essential biologic processes \[[@cit0038], [@cit0039]\]. The insights into the role of PI3K/Akt in human diseases provide a wide spectrum of therapeutic strategies. It has been reported that PI3K/Akt is highly expressed in human as well as murine atherosclerotic lesions, and the pharmacological PI3K inhibitor AS605240, 5-quinoxilin-6-methylene-1,3-thiazolidine-2,4-dione, significantly reduced early atherosclerotic lesions in apolipoprotein E (Apo-E)-null mice \[[@cit0040]\]. A similar effect was also observed in an atherosclerotic lesion of LDL receptor-deficient mice in response to AS605240, suggesting that this protein is a promising target for the treatment of atherosclerosis \[[@cit0039]\]. In addition, topotecan, a water soluble camptothecin analog, inhibits vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bEGF)-induced vascular endothelial cell migration via downregulation of the PI3K/Akt signaling pathway \[[@cit0041]\]. In contrast, the results of the current study show that hinokitiol treatment did not alter the expression of PDGF-BB-induced PI3K. It evidently confirms that hinokitiol inhibits PDGF-BB-stimulated VSMC proliferation, through enhancing the p21 and p53 signaling pathway ([Figure 5](#f0005){ref-type="fig"}).

![Hypothetical scheme of the inhibitory mechanism of hinokitiol in VSMC proliferation](AMS-14-32528-g005){#f0005}

In conclusion, these results suggest that hinokitiol may inhibit vascular smooth muscle cell proliferation via the p21/p53 signaling pathway, followed by inhibiting DNA synthesis. Proliferation of vascular smooth muscle cells has been identified to play a critical role in the pathogenesis of atherosclerosis. Hinokitiol may be a promising candidate for the treatment of atherosclerosis and related cardiovascular diseases.
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